Which immunization plan is most appropriate for a child who recently had Kawasaki disease and was treated with IVIG?

Which immunization plan is most appropriate for a child who recently had Kawasaki disease and was treated with IVIG?

• A. DTaP, OPV, and MMR today
• B. MMR only
• C. None; immunizations at school next year
• D. DTaP and IPV today, and MMR in about 1 month

Answer: (D)

When IVIG has been given recently, the immune system is surrounded by passive antibodies from the infusion. Those antibodies can interfere with vaccines that rely on the body’s own immune response to a replicating organism. Live vaccines, like MMR, are particularly susceptible to this interference because the vaccine uses live attenuated viruses to stimulate immunity. Inactivated vaccines, such as DTaP and IPV, do not rely on viral replication and can be given even when passive antibodies are present. So the best plan is to proceed with vaccines that are inactivated now to ensure ongoing protection, and delay the live vaccine until the IVIG antibodies have waned. Administering DTaP and IPV today provides protection against diphtheria, tetanus, pertussis, and polio. Scheduling MMR about a month later allows time for IVIG-derived antibodies to decline, reducing the risk of interference and ensuring an adequate immune response. In contrast, giving MMR today would risk reduced vaccine effectiveness due to the lingering IVIG antibodies, and waiting entirely until next year would leave gaps in protection.

When IVIG has been given recently, the immune system is surrounded by passive antibodies from the infusion. Those antibodies can interfere with vaccines that rely on the body’s own immune response to a replicating organism. Live vaccines, like MMR, are particularly susceptible to this interference because the vaccine uses live attenuated viruses to stimulate immunity. Inactivated vaccines, such as DTaP and IPV, do not rely on viral replication and can be given even when passive antibodies are present.

So the best plan is to proceed with vaccines that are inactivated now to ensure ongoing protection, and delay the live vaccine until the IVIG antibodies have waned. Administering DTaP and IPV today provides protection against diphtheria, tetanus, pertussis, and polio. Scheduling MMR about a month later allows time for IVIG-derived antibodies to decline, reducing the risk of interference and ensuring an adequate immune response.

In contrast, giving MMR today would risk reduced vaccine effectiveness due to the lingering IVIG antibodies, and waiting entirely until next year would leave gaps in protection.